Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Binds hormone or other secreted growth regulatory factor,...
Reexamination Certificate
2005-03-08
2005-03-08
Gambel, Phillip (Department: 1644)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Binds hormone or other secreted growth regulatory factor,...
C424S130100, C424S141100, C424S145100, C530S387100, C530S388100, C530S388230
Reexamination Certificate
active
06863890
ABSTRACT:
The present disclosure concerns the treatment of a patient with autoimmune disease, including AIDS, by neutralizing, removing or inhibiting different types of interferons, tumor necrosis factor, HLA class II antigens, IgE, and other pathological factors and/or their receptors, as well as neutralizing, removing or inhibiting autoantibodies, including antibodies to target cells, CD4 cells and DNA. Treatment comprises administration of an autoimmune inhibitor, or extracorporeal exposure of the patient's fluid to an immunosorbent comprising an autoimmune inhibitor, followed by return of the treated fluid to the patient; or it comprises a combined therapy involving extracorporeal immunosorption in conjunction with the administration of an autoimmune inhibitor.
REFERENCES:
patent: 4362155 (1982-12-01), Skurkovich et al.
patent: 4605394 (1986-08-01), Skurkovich et al.
patent: 4824432 (1989-04-01), Skurkovich et al.
patent: 6190691 (2001-02-01), Mak
patent: WO 9216553 (1992-10-01), None
patent: 9426307 (1994-11-01), None
Skolnick Trends In Biotech 18: 34-39 (2000).*
Lederman et al. Molecular Immunology 28: 1171-1181 (1991).*
Li et al. PNAS 77: 3211-3214 (1980).*
Skurkovich et al. Medical Hypotheses 42: 27-35 (1994).*
Merck Manual of Medical Information's (1997), pp. 1018-1019.*
Janeway et al Immunobiology 3rd Edition Garland Press NY 1997, Figure 7.31, p. 7:27.
Probert et al PNAS 92(24): 11294-8, 1995.
Abaza et al J. Protein Chem. 11(5):433-444, 1992.
Aderka et al., “Correlation between Serum Levels of Soluble Tumor Necrosis Factor Receptor and Disease Activity in Systemic Lupus Erythematosus,”Arthritis Rheum. 36(8):1111-1120 (1993).
Altomonte et al., “Serum Levels of Interleukin-1b, Tumor Necrosis Factor-a and Interleukin-2 in Rheumatoid Arthritis, Correlation with Disease Activity.”Clin. Rheum. 11(2):202-205 (1992).
Bevan et al., “Interferon Induced Parotitis and Epididymitis,”Lancet2:561 (1985).
Biglino et al., “Spontaneous Release of Interferon as a Predictor of Clinical Evolution in HIV-Positive Subjects,”Infection 19(1):11/7-11/17 (1991).
Billard et al., “IFNα in Vivo Enhances Tumor Necrosis Factor Receptor Levels on Hairy Cells,”J. Immunol. 145:1713-1718 (Sep. 1990).
Brahn et al., “Effects of Tumor Necrosis Factor Alpha (TNFα) on Collagen Arthritis,”Lymphokine and Cytokine Res. 11(5):253-256 (1992).
Brennan et al., “TNFα-A Pivotal Role in Rheumatoid Arthritis,”Brit. J. Rheum. 31(5):293-8 (1992).
Brod et al., “Interferon-β1bTreatment Deceases Tumor Necrosis Factor-α and Increases Interleukin-6 Production in Multiple Sclerosis,”Neurology46: 1633-1638 (Jun. 1996).
Burton, “Human Monoclonal Antibodies, Achievement and Potential,”Hospital Practice667-74 (Aug. 1992).
Carpenter et al., “The Pathogenesis of Autoimmunity in New Zealand Mice,”Lab Invest. 23:628-634 (1970).
Chu et al., “Detection of Cytokines at the Cartilage/Pannus Junction in Patients with Rheumatoid Arthritis: Implications for the Role of Cytokines in Cartilage Destruction and Repair,”Brit. J. Rheum. 31(10):653-661 (1992).
Chazerain et al., “Rheumatoid Arthritis-like Disease after Alpha-Interferon Therapy,”Ann. Intern. Med. 116:427 (Mar. 1992).
Conlon et al., “Exacerbation of Symptoms of Autoimmune Disease in Patients Receiving Alpha-Interferon Therapy,”Cancer 65:2237-2242 (1990).
Danis et al., “Circulating Cytokine Levels in Patients with Rheumatoid Arthritis: Results of a Double Blind Trial with Sulphasalazine,”Ann. Rheum. Disease 51(8):946-950 (1992).
Deleuran et al., “Localization of Tumor Necrosis Factor Receptors in the Synovial Tissue and Cartilage-Pannus Junction in Patients with Rheumatoid Arthritis,”Arthritis Rheum. 35(10):1170-78 (1992).
DeStefano et al., “Acid-Labile Human Leukocyte Interferon in Homosexual Men with Karposi's Sarcoma and Lymphadenopathy,”J. Infec. Disease 146:451-455 (1982).
Dorsett et al., “Anti-Lymphocyte Antibodies in Patients with the Acquired Immune Deficiency Syndrome,”Am. J. Med. 78:621-626 (1985).
Elliott et. al., Treatment of Rheumatoid Arthritis with Chimeric Monoclonal Antibodies to TNF-α: Safety, Clinical Efficacy and Control of the Acute Phase Response,J. Cellular Biochemistry. Suppl. 17B:145 (1993).
Elliott et al., “Repeated Therapy with Monoclonal Antibody to Tumor Necrosis Factor α (cA2) in Patients with Rheumatoid Arthritis,”Lancet344:1125-1127 (1994).
Engleman et al., Treatment of NZB/NZW F1Hybrid Mice withMycobacterium bovisStrain BCG or Type II Interferon Preparations Accelerates Autoimmune Disease,Arthr. Rheum. 24:1396-1402 (1981).
Fattovich et al., “Autoantibodies during Interferon-α Therapy for Chronic Hepatitis B,”Br. J. Med. Virol. 34:132-135 (1991).
Feldman, et al., “Interferons and Autoimmunity,” InIFN 9,Academic Press, p. 75 (1987).
Foulis et al., “Immunoreactive α-Interferon in Insulin-Secreting β Cells in Type I Diabetes Mellitus,”Lancet2:1423-1427 (1987).
Gendelman et al., “Induction of IFNα in Peripheral Blood Mononuclear Cells by HIV-Infected Monocytes,”J. Immunol. 148:422-429 (1992).
Graninger et al., “Induction of Systemic Lupus erythematosus by Interferon-γ in a Patient with Rheumatoid Arthritis,”J. Rheumatol.18:1621-1622 (1981).
Gringeri et al., “Anti-Alpha Interferon Immunization Safety and Immunogenicity in Asymptomatic II HIV Positive Patients at High Risk of Disease Progression,”Cell. Mol. Biol. 41(3):381-387 (1995).
Gringeri et al., “Absense of Clinical, Virological, and Immunological Signs of Progression in HIV-1-Infected Patients Receiving Active Anti-Interferon-α Immunization: A 30-Month Follow-Up Report,”J. Acquir. Immun. Defic. Syndr.13:55-67 (1996).
Heremans et al., “Interferon Treatment of NZB Mice Accelerated Progression of Autoimmune Disease,”Infect. Immun. 21:925-930 (1978).
Hess et al., “Tumor Necrosis factor and Interferon as Prognostic Markers in Human Immunodeficiency Virus (HIV) Infection,”Infection 19. Suppl. 2:S93-97 (1991).
Hirano et al., “Interleukin-6 and Its Relation to Inflammation and Disease,”Clin. Immunol. 62:S60-S65 (1992).
Holt et al., “Cytokine Inter-Relationships and the Association with Disease Activity in Arthritis,”Brit J. Rheum. 21(11):725-733 (1992).
Hooks et al., “Immune Interferon in the Circulation of Patients with Autoimmune Disease,”N. Eng. J. Med.301:5-8 (1979).
Johnson et al., “The Role of Antimyosin Antibodies in Acute Myocardial Infarction,”Sem. Nuc. Med. 19:238 (1989).
Robert E. Walker et al., “Inhibition Of Immunoreactive Tumor Necrosis Factor-α by a Chimeric Antibody in Patients Infected with Human Immunodeficiency Virus Type 1”, The Journal Of Infectious Diseases (1996) 174:63-8.
Stephen C Piscitelli et al., “Immune-Based Therapies For Treatment Of HIV Infection”, The Annals of Pharmacotherapy (1996) Jan., vol. 30 pp. 62-76.
R. Le Naour et al., “Treatment of human monocyte-derived macrophages with a TNFα synthesis inhibtor prior to HIV1 infection: consequences on cytokine productin and viral replication,” Res. Virol. (1994) 145, 199-207.
Larrey et al., “Exacerbation of Multiple Sclerosis after the Administration of Recombinant Human Interferon Alfa,”JAMA261:2065 (1989).
Lau et al., “Regulation of Tumor Necrosis Factor Receptor Expression by Acid-Labile Interferon-α from AIDS Sera,”AIDS Research and Human Retroviruses 7:545-552 (1991).
Leinonen et al., “Circulating Immune Complexes Containing Chlamydial Lipopolysaccharide in Acute Myocardial Infarction,”Microbiol. Path. 9:67-73 (1990).
Libikováet al., “Orbiviruses of the Kemerovo Complex and Neurological Disease,”Med. Microbiol. Imm
Skurkovich Boris
Skurkovich Simon V.
Advanced Biotherapy, Inc.
Gambel Phillip
Morgan & Lewis & Bockius, LLP
LandOfFree
Treatment of AIDS with antibodies to gamma interferon, alpha... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Treatment of AIDS with antibodies to gamma interferon, alpha..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treatment of AIDS with antibodies to gamma interferon, alpha... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3368131